B+
Bull case
25%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
NVCT
NuvectisFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
If NXP900's Phase 1b program begins to show biomarker-linked activity in enrolled monotherapy or EGFR-combination cohorts, NVCT could re-rate because management has described active enrollment in key Phase 1b studies and the latest confirmed financial update indicates runway through several of those milestones [#8-K-2026-02-11].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta 0.0.
What can break
As of 2026-05-04, no verified Q1 2026 earnings release or 10-Q was available in the evidence packet, leaving surprise, guidance, and market-reaction evidence unavailable.
Momentum
96
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.50 · Bull $14.00 · Bear $4.50Analysis 2026-05-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $35.40
Why
Momentum96 · Δ7d +1.3
Value41 · Δ7d 0.0
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta 0.0.
Contradictions & invalidation
- • As of 2026-05-04, no verified Q1 2026 earnings release or 10-Q was available in the evidence packet, leaving surprise, guidance, and market-reaction evidence unavailable.
- • Financing risk remains structural even with current runway because the company says additional capital will be needed to complete development [#10-K-2026-02-11].
- • The May 4, 2026 scheduled earnings follow-up produced no confirmed new company earnings release, 8-K, or 10-Q in the provided evidence, so there is no fresh beat/miss, guidance, or analyst-revision signal to validate a thesis change.
Catalyst clock
2026-05-04
Q1 2026 earnings packet remains unconfirmed, leaving a near-term information gap
Lead driver: Value · See fundamentals
Momentum
96
9% active weight
Current posture
7d trendImproving
Δ7d
+1.3
Δ21d
-0.6
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
0
62% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade F. Momentum 96.5 / Value 41.2 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-04. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$621.66M
Beta
-0.31
Shares Out
32.58M
P/E (TTM) · Derived
-14.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-23.16
Rev YoY
-
EPS YoY
+0.9%
Gross Margin
-
Op Margin
-
Net Debt
-$31.63M
Current Ratio
1.68
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data